The Oncology Institute Inc Stock Price, News & Analysis

The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, has appointed Kristin England as its new Chief Administrative Officer (CAO), effective July 7, 2025. In this newly created position, England will be responsible for overseeing Enterprise Central Business Operations and Technology Strategy across TOI's national operations.

England joins TOI with over 20 years of healthcare management experience, previously serving as a senior executive at McKesson's US Oncology Network, where she specialized in revenue cycle optimization and practice management systems improvement. CEO Daniel Virnich emphasized that England's appointment comes at a crucial time as TOI focuses on scaling its MSO model and strengthening its value-based care approach.

The Oncology Institute (NASDAQ: TOI) has announced a significant partnership with SilverSummit Healthplan, becoming the exclusive oncology provider for over 80,000 Medicaid patients in Nevada, effective July 1. This expansion marks an important step in TOI's mission to provide value-based cancer care to underserved communities.

The partnership will operate through three Nevada locations in Las Vegas, Henderson, and Spring Valley, offering comprehensive cancer care services to SilverSummit Healthplan members. This collaboration aligns with TOI's track record of serving Medicaid patients and SilverSummit's commitment to providing high-quality healthcare access to its members.

The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the US, will be added to both the Russell 2000® and Russell 3000® indexes following the 2025 annual reconstitution, effective June 27. The inclusion is based on TOI's market capitalization ranking among the 4,000 largest US stocks as of April 30. This milestone reflects TOI's growth and market presence in value-based cancer care. The Russell indexes, which benchmark approximately $10.6 trillion in assets, are widely used by investment managers and institutional investors for index funds and active investment strategies. CEO Daniel Virnich emphasized that this inclusion demonstrates TOI's successful execution and innovative approach to cancer care, while reinforcing their commitment to patient outcomes and shareholder value.

The Oncology Institute (NASDAQ: TOI) reported strong Q1 2025 financial results. Revenue reached $104.4 million, up 10.3% year-over-year, with notable performance from their Retail Pharmacy and Dispensary segment contributing $49.3 million. The company posted a net loss of $19.6 million, slightly improved from $19.9 million in Q1 2024. TOI secured multiple capitated contract wins, adding over 100,000 lives across Florida, California, and Nevada markets. The company reaffirmed its 2025 guidance, projecting revenue of $460-480 million and gross profit of $73-82 million. TOI successfully raised $16.5 million through a private placement and expects to achieve cash flow positivity and profitability in the second half of 2025, with full-year profitability targeted for 2026.

The Oncology Institute (NASDAQ: TOI) has appointed Dr. Jeffrey Langsam as its new enterprise Chief Clinical Officer (CCO), effective May 13th, 2025. In this role, Dr. Langsam will oversee therapeutics, including pathway and procurement decisions, utilization management, and MSO practice clinical engagement.

Dr. Langsam joins TOI from Cigna Healthcare, where he served as National Director of Oncology and Senior Medical Director in the Specialty Pharmacy Division. His previous experience includes roles as Regional Medical Director at Aetna and clinical faculty at the University of Connecticut, where he practiced as an oncologist.

The appointment comes as TOI experiences acceleration in new value-based partnerships and growth in its MSO model across the country.

The Oncology Institute (NASDAQ: TOI), a leading value-based oncology group in the United States, announced its participation in the upcoming B. Riley's 25th Annual Institutional Investor Conference. The event will take place on May 21st, 2025, in Marina Del Rey, CA. The company will be represented by CEO Dr. Daniel Virnich and CFO Rob Carter.

The Oncology Institute (NASDAQ: TOI) has been selected to present significant findings at the upcoming ASCO Annual Meeting regarding their High-Value Cancer Care (HVCC) model. The study demonstrates remarkable improvements in patient care and cost efficiency:

Key outcomes include:

• 53% reduction in Emergency Department use
• 68% decrease in hospitalizations
• 75% lower odds of acute care facility death
• $12,000 cost savings per enrolled patient

According to TOI's Chief Medical Officer, Dr. Yale Podnos, these results validate their coordinated care approach in delivering superior clinical outcomes while significantly reducing costs for patients and payor partners.

The Oncology Institute (TOI), a leading value-based oncology group in the United States, has scheduled its first quarter 2025 financial results announcement. The company will release its Q1 2025 results after market close on Wednesday, May 14, 2025, followed by a conference call at 5:00 p.m. Eastern Time.

Investors can access the conference call via phone (1-877-407-0789 for domestic, 1-201-689-8562 for international) or through a simultaneous webcast on TOI's Investor Relations website. A replay will be available for one week until May 21, 2025, using passcode 13752832.

The Oncology Institute (NASDAQ: TOI) has announced an enterprise-wide expansion of its strategic partnership with Helios Clinical Research, building upon their existing collaboration in Florida. The expanded partnership aims to enhance access to cancer clinical trials across TOI's markets.

The collaboration focuses on integrating clinical research into community oncology settings, with key benefits including:

• Increased patient access to leading-edge therapies
• Streamlined study activation and enrollment processes
• Enhanced trial performance through unified oversight
• Improved infrastructure for regulatory and operational support

TOI CEO Daniel Virnich emphasized that this expansion will help scale their research infrastructure while maintaining focus on patient care. Chief Medical Officer Yale Podnos highlighted the initiative's goal of making clinical research a routine part of patient care across all markets, with a shared commitment to advancing health equity in oncology research.